AUPH today
$16.33+$0.12 (+0.74%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bullish
1 hourBullish
15 minLeaning Bearish
5 minBearish
Daily trend turns up above $19.25
Key levels
Resistance$17.40
Resistance$16.59
Support$15.95
Support$14.90
Latest news & SEC filings
AnalystRBC Capital keeps Sector Perform on Aurinia Pharmaceuticals, lifts target to $18
AnalystRBC Hikes Its Valuation Level for Aurinia Shares to $18
EarningsAurinia Pharmaceuticals releases Q3 and year-to-date 2026 financials
All AUPH news →About Aurinia
Aurinia is a biopharmaceutical company that develops and sells treatments for autoimmune diseases. Its main product is LUPKYNIS, an oral therapy for adults with active lupus nephritis, which it sells in the United States through specialized dispensing channels. The company also supplies LUPKYNIS to its partner Otsuka, which markets it in Japan, Europe, the UK and Switzerland, and is developing aritinercept for autoimmune conditions.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
Aurinia Pharmaceuticals Inc. (AUPH)
What Is the Price Target for AUPH?
SEPT Low Target
$14.45
SEPT Mid Target
$17.00
SEPT High Target
$19.55
Analyst Consensus
$17.00
Is AUPH a Buy or Sell Right Now?
Thesis
- •Revenue growing 20.4% YoY with STRONG trend — consistent growth.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AUPH.
Start Free Trial →Is AUPH Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$15.98
49
Moat Score
NARROW
6/9
Piotroski Score
8.8
Altman Z-Score
What Is Smart Money Doing with AUPH?
Insider Signal
BUYING
11 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Robertson Stephen P. | officer | Sale | 11,939 | $190K | Sep 10, 2026 |
| TANG KEVIN | director officer 10% owner | Buy | 206,005 | $3.1M | Jun 2, 2026 |
| TANG KEVIN | director officer 10% owner | Buy | 343,521 | $5.2M | Jun 1, 2026 |
| TANG KEVIN | director officer 10% owner | Buy | 99 | $2K | Jun 1, 2026 |
| TANG KEVIN | director officer 10% owner | Buy | 2,299 | $35K | May 29, 2026 |
| TANG KEVIN | director officer 10% owner | Buy | 262,682 | $4.0M | May 29, 2026 |
| Cole Ryan | officer | Buy | 116,144 | - | May 18, 2026 |
| Robertson Stephen P. | officer | Buy | 115,541 | - | May 18, 2026 |
| Hearne Michael S | officer | Buy | 116,144 | - | May 18, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AUPH Growth Story
Revenue YoY
20.4%
3yr Revenue CAGR
28.3%
EPS Growth YoY
5075%
FCF Growth YoY
N/A%
Revenue Trend
STRONG
Dark Pool Trades for AUPH
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AUPH, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:35:20 | $16.34 | 1,553 | $$25K | BUY |
| 18:31:45 | $16.32 | 2,600 | $$42K | BUY |
| 18:26:10 | $16.26 | 1,700 | $$28K | SELL |
| 18:24:56 | $16.30 | 1,200 | $$20K | SELL |
| 18:10:38 | $16.30 | 1,000 | $$16K | BUY |
5 dark pool trades shown · $$131K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for AUPH
PREVIEWSEPT Investing provides real-time options flow tracking for AUPH, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $17 | Apr 16 | 155 | $$340 | 2 | SWEEP |
| CALL | $17 | Apr 16 | 155 | $$875 | 5 | SWEEP |
2 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Aurinia Pharmaceuticals Inc. (AUPH) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AUPH — frequently asked questions
What is AUPH stock price today?
Aurinia Pharmaceuticals Inc. (AUPH) is at $16.33, up 0.74% (+$0.12) at the Nov 12, 2026 close.
Why is AUPH stock moving today?
Latest AUPH news — Nov 2, 2026: RBC Capital keeps Sector Perform on Aurinia Pharmaceuticals, lifts target to $18 · Nov 2, 2026: RBC Hikes Its Valuation Level for Aurinia Shares to $18
What is the AUPH price target?
The average analyst price target for AUPH is $17.00, ranging from $16 to $18, based on 2 analysts. Latest: TD Cowen maintains on Oct 21, 2026.
What do analysts rate AUPH?
Analyst ratings for AUPH: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
Did AUPH beat earnings?
AUPH last reported on Aug 6, 2026: EPS $0.28 vs $0.24 expected — a beat of 16.7%.
What is AUPH's P/E ratio?
AUPH trades at a P/E of 7.5 vs a Healthcare average of 18.4.
Does AUPH pay a dividend?
AUPH does not currently pay a dividend.
What are AUPH support and resistance levels?
Support: $15.95, $14.90, $14.36. Resistance: $16.59, $17.40, $19.25.
What are insiders doing with AUPH?
Insider activity: BUYING, 11 buys and 1 sells in the last 90 days.
What is the latest news on AUPH?
Nov 2, 2026: RBC Capital keeps Sector Perform on Aurinia Pharmaceuticals, lifts target to $18 · Nov 2, 2026: RBC Hikes Its Valuation Level for Aurinia Shares to $18 · Oct 30, 2026: Aurinia Pharmaceuticals releases Q3 and year-to-date 2026 financials